The aim of this study was to determine the chelating ability of Sulbactomax drug in arsenic pre-exposed rats. 24 rats were divided into I to III groups. Group I was control while Groups II to III were arsenic exposed and arsenic plus Sulbactomax treated group. Arsenic toxicity was induced via intraperitoneally administration of arsenic trioxide (As2O3) 10 mg/kg body weight/day for three weeks. Toxicity was confirmed by decreased body weight, increased body temperature, loss ofappetite and decreased hemoglobin levels in all groups except Group I. After confirmation of these symptoms, drug was administered via intravenous route for three week treatment. At the end of the study, blood samples were collected and the arsenic, zinc concentration, hemoglobin level and δ -aminolevulinic acid dehydrates activity were measured in the blood while other parameters were measured in the plasma sample. Our results revealed that zinc concentration, hemoglobin level, δ -aminolevulinic acid dehydratase, catalase and superoxide dismutase (SOD) enzyme activities significantly increased, while arsenic concentration, lipid peroxidation level, myloperoxidase enzyme activity, tumor necrosis factor TNF-α and IL-6 levels significantly reduced in Group III as compared to Group II. So, the findings concluded that administration of Sulbactomax drug act as an antioxidant and chelating agent that reduce arsenic metal and freeradical mediated tissue injury.
Key words: Arsenic, Sulbactomax, antioxidant enzymes, cytokines parameters, arsenic, zinc.
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0